Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective.

Mary-Ellen Taplin

    Reviews in Urology
    |September 21, 2006
    PubMed
    Summary

    Defining biochemical relapse after prostate cancer treatment remains challenging. Early prostate-specific antigen (PSA) rise signals recurrence, but treatment options lack proven survival benefits, necessitating clinical trials.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    HSD3B1 links ileal steroid metabolism to bile acid regulation in patients with prostate cancer.

    The Journal of clinical investigation·2026
    Same author

    Perioperative Apalutamide in High-Risk Localized Prostate Cancer.

    The New England journal of medicine·2026
    Same author

    Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate Cancer.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026
    Same author

    Impact of Pre-treatment Testosterone Levels on Severity of Adverse Effects in Men on Androgen Deprivation Therapy for Prostate Cancer.

    Andrology·2026
    Same author

    FORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and Apalutamide.

    European urology·2026
    Same author

    Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Area of Science:

    • Oncology
    • Urology

    Background:

    • The definition of biochemical relapse after prostate cancer treatment (prostatectomy or radiation) lacks consensus.
    • Prostate-specific antigen (PSA) is a sensitive marker for occult recurrence, but a PSA relapse does not always correlate with clinical progression or mortality.

    Purpose of the Study:

    • To review data on features of PSA relapse after prostatectomy and radiation.
    • To explore various treatment options for biochemical relapse and assess their efficacy.

    Main Methods:

    • Review of retrospective, single-institution trials.
    • Analysis of prostate-specific antigen (PSA) doubling time and time to first PSA elevation.
    • Evaluation of current and future treatment strategies for biochemical relapse.

    Main Results:

    • PSA doubling time and time to first PSA elevation are associated with clinical progression.
    • No current standard treatment for biochemical failure offers proven benefits in quality of life, time to metastases, or survival.
    • Observation, hormone therapy, or clinical trials are current options based on PSA doubling time and patient preference.

    Conclusions:

    • Establishing a clear definition for biochemical relapse is crucial.
    • Early chemotherapy combined with hormone therapy shows promise.
    • Enrollment in clinical trials is encouraged to establish evidence-based standards of care for prostate cancer recurrence.

    Related Experiment Videos